Which statement about ranolazine (Ranexa) is true for a patient with chronic angina?

Ranolazine (Ranexa) is an antianginal agent that is unique from traditional therapies like beta blockers and calcium channel blockers. Although it's primarily used to treat chronic angina, it does not typically serve as a first-line or sole therapeutic option on its own. Instead, it is often used in conjunction with other medications, including beta blockers, calcium channel blockers, or long-acting nitrates.

The correct statement regarding ranolazine for a patient with chronic angina is that it requires concurrent treatment with a calcium channel blocker. This is due to the way ranolazine works—inhibiting the late sodium current during ischemia, which helps improve myocardial metabolism and reduce anginal symptoms. It does not exert significant effects on heart rate or blood pressure, making it ideal as an adjunct to the aforementioned medications rather than a replacement.

Additionally, ranolazine can be safely used alongside nitroglycerin. This combination can offer additional control of angina symptoms, emphasizing its role as part of a broader management plan rather than an isolated treatment option.